A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache
Sponsor study identifier
interventional
60
1 country
26
Study Start
January 2002
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2003
Actual (reported)Study Completion
July 2003
Actual (reported)This is a 49-day study to evaluate the effectiveness of Intranasal Civamide (Zucapsaicin) in the treatment of an episodic cluster headache period compared to placebo (medically inactive substance which does not contain any active ingredients).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2003
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2002
Date type not reportedThis date has not been verified as actual or estimated.
April 11, 2002
Actual (reported)April 12, 2002
Actual (reported)July 2003
Actual (reported)July 2003
Actual (reported)Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Valley Neurological Headache & Research Center
Phoenix, Arizona, 85020, United States
Neurological Associates of Tucson
Tucson, Arizona, 85712, United States
Northern California Headache Clinic
Mountain View, California, 94040, United States
San Francisco Clinical Research Center
San Francisco, California, 94109, United States
California Medical Clinic for Headache
Santa Monica, California, 90404, United States
New England Center for Headache, PC
Stamford, Connecticut, 06902, United States
Neurology Clinical Research, Inc.
Scott B. Phillips, M.D.
Winston Laboratories
First Submitted
April 11, 2002
First Posted
April 12, 2002
Study Start
January 2002
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2003
Actual (reported)Episodic CandClus2: A randomized, placebo-controlled, triple blind study of candesartan in adults with episodic cluster headache
Plantation, Florida, 33324, United States
Neurology and Headache Specialists of Atlanta
Decatur, Georgia, 30033, United States
Diamond Headache Clinic
Chicago, Illinois, 60614, United States
Boston Clinical Research Center
Wellesley Hills, Massachusetts, 02481, United States
Michigan Headache Pain & Neurological Institute
Ann Arbor, Michigan, 48104, United States
Henry Ford Hospital Department of Neurology
Detroit, Michigan, 48202, United States
Department of Neurology Mayo Clinic
Rochester, Minnesota, 55905, United States
Mercy Health Research
Chesterfield, Missouri, 63017, United States
Headache Care Center/Clinvest
Springfield, Missouri, 65804, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
New York Headache Center
New York, New York, 10021, United States
The Headache Wellness Center
Greensboro, North Carolina, 27401, United States
Cincinnati Headache Clinic
Cincinnati, Ohio, 45219, United States
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
University of Oklahoma
Oklahoma City, Oklahoma, 73104, United States
Neurological Associates of Tulsa, Inc.
Tulsa, Oklahoma, 74136, United States
Jefferson Headache Center
Philadelphia, Pennsylvania, 19107, United States
Nashville Neuroscience Center
Nashville, Tennessee, 37203, United States
Houston Headache Clinic
Houston, Texas, 77004, United States
The Neurology and Headache Treatment Center (Innovative Clinical Research)
Alexandria, Virginia, 22304, United States
Study Completion
July 2003
Actual (reported)Last Updated
June 10, 2011
Record last verified: 2011-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: